Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）

This study is testing whether adding the drug anlotinib (an anti-cancer targeted therapy) to radiation therapy before surgery improves outcomes in people with soft tissue sarcoma of the limbs or trunk — a rare type of cancer affecting connective tissue. **You may be eligible if...** - You are over 18 years old - You have a confirmed soft tissue sarcoma of the arm, leg, or trunk (torso) - Your cancer has been reviewed by a specialist pathologist and deemed suitable for preoperative radiation and limb-sparing surgery - You are in reasonable health (ECOG 0–3) - You are willing to use contraception **You may NOT be eligible if...** - You have already had your tumor removed elsewhere - You have conditions that would make anlotinib unsafe (e.g., active bleeding, uncontrolled high blood pressure, severe heart or liver problems) - Your tumor is a type excluded from the study (e.g., DFSP, desmoid tumor) - You have another cancer diagnosed in the past 5 years - There is evidence of cancer spread to other parts of the body - You have already received radiation to the same area Talk to your doctor to see if this trial is right for you.